Prussian Blue (P.B.) has been shown to bind 137Cs in the lumen of the mammalian gut forming a stable complex and thus increasing the faecal loss of 137Cs from the body. The effect of P.B., provided in drinking water, on the excretion of intraperitoneally (I.P.) administered 137Cs from rats of various ages, has been investigated. In 19 week old rats, the body burden of 137Cs was reduced to 34% of the controls at 1 week after injection, whilst in 9- and 4- week old animals, the corresponding values were 28 and 9% respectively. Analysis of tissues has suggested that the main limiting factor governing the rate of excretion of 137Cs during P.B. therapy is the turnover rate of 137Cs in muscle tissue. The turnover rate declines with increasing age and this is reflected by a decreasing efficiency of the P.B, in removing 137Cs from the animal. Rubidium-86 has a similar distribution in the rat to 137Cs but a faster turnover rate in muscle tissue. Following i.p. administration of 86Rb to 11 week old rats, P.B. treatment reduced the whole body biological half time of retention of this radionuclide from 10.3 days to 1.7 days, resulting in the body content of 86Rb being reduced to 9% of the controls at 7 days after injection. It has also been demonstrated that P.B. can be successfully used to reduce the body content of 137Cs fed chronically to rats.